Synonyms: compound 3 [WO2016050171A1] | XZP-3621 | XZP3621
Compound class:
Synthetic organic
Comment: The chemical structure for dirozalkib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as an anaplastic lymphoma kinase (ALK) inhibitor, with antineoplastic potential. The structure is claimed in Xuanzhu Biopharmaceutical (a subsidiary of Sihuan Pharmaceutical) patent WO2016050171A1 [1]. It is plausible that dirozalkib is the INN for Sihuan's clinical lead XZP-3621, which is in fact a dual-target ALK/ROS1 tyrosine kinase inhibitor. XZP-3621 is proposed to tackle ALK resistance mutations in tumours, that are associated with other ALK inhibitors.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|